Five things for pharma marketers to know: Tuesday, July 26, 2016



1. Revenue from Gilead Sciences' hepatitis-C portfolio fell 19% during the second quarter. The drugmaker blamed lower-than-expected sales on pricing pressure from payers in light of competition from companies like AbbVie and Merck. (WSJ)

2. The Democratic party unveiled its policy platform last week, advocating for a public health insurance option and that those older than 55 years old be able to opt in to Medicare. The platform also said that Democratic leadership would “crack down on price gouging” by drug companies and limit the amount of money that Americans pay out of pocket for prescription drugs each month. Sen. Bernie Sanders (I-Vt.) told attendees at the Democratic National Convention, which started Monday, that “the greed of the drug companies must end” and Medicare should be able to negotiate drug prices.

3. Janssen announced a immuno-oncology collaboration with Bristol-Myers Squibb to investigate the combination of lung-cancer drug Opdivo with an experimental immunotherapy, JNJ-64041757, which was developed by Janssen. Janssen will conduct the study.

4. Eli Lilly's profit in the second quarter of 2016 matched analysts' estimates. The drugmaker cited growing U.S. sales of erectile dysfunction pill Cialis and diabetes treatment Humalog. The company's revenue rose 8.7% to $5.4 billion during the quarter, compared to the same period a year ago. (Bloomberg)

5. ICYMI: Forty percent of the ads that ran during the ABC, CBS, and NBC broadcast of the Republican National Convention were for drugmakers, prescription drugs or over-the-counter drugs. (Stat)